US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Antibody Technologies Market Research Reports & Industry Analysis

RSS Feeds

Antibody Technologies Industry Research & Market Reports

< prev 1    3  4  5  6  7  8  9  10  
Engineered TCR and CAR Immunotherapeutics 2015
3/11/2015 | published by: La Merie Publishing
... promising emerging technologies in immuno-oncology apart from immune checkpoint modulators. The relevance of TCR targeting and engineered T cells is reflected by impressive clinical results with CD19 chimeric antigen receptor (CAR) T cells and outstanding ...  |  read more...
USD 2,630
Antibody Deals and Alliances of 2014
3/1/2015 | published by: Current Partnering
... during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. ...  |  read more...
USD 1,495
Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015
3/1/2015 | published by: DelveInsight
... provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, ...  |  read more...
USD 3,500
Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin
2/15/2015 | published by: La Merie Publishing
... antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...  |  read more...
USD 390
Competitor Analysis: Specific and Bispecific Her3 Antibodies
2/16/2015 | published by: La Merie Publishing
... Her3 and Her2 or EGF-R or other targets for treatment of cancer as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...  |  read more...
USD 260
Global MABS Industry 2014 Market Research Report
1/10/2015 | published by: 9Dimen Research
... the main countries (United States, Germany, Japan and China). The report firstly introduced the MABS basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so ...  |  read more...
USD 2,850
Global Markets for Research Antibodies
1/1/2015 | published by: BCC Research
... a compound annual growth rate (CAGR) of 6.2% for the period 2014-2019. This report provides: An overview of the global market for antibodies used in research. Analyses of global market trends, with data from 2013, ...  |  read more...
USD 6,650
Antibodies in Oncology: Drug Pathway Analyzer 2015
1/12/2015 | published by: BioSeeker Group AB
... than 126 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 283 drug targets that are included in this drug-pathway analyzing tool. No less than ...  |  read more...
USD 6,746
Antibodies in Oncology Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... of therapeutic antibodies. There are today 354 companies plus partners developing 707 antibody drugs in 1875 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over ...  |  read more...
USD 6,746
Biosimilar Monoclonal Antibodies: World Industry and Market Outlook 2015-2025
1/19/2015 | published by: Visiongain
... therapies (mAbs)? Can that emerging market, with vast potential, achieve expected sales growth? See what’s likely there, staying ahead. Now, in an updated study, you explore that industry’s research and development (R&D). And assess forecasted ...  |  read more...
USD 2,788
Enzyme-Linked Immunosorbent Assay (ELISA)
1/1/2015 | published by: Global Industry Analysts
... provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is ...  |  read more...
USD 4,950
Intravenous Immunoglobulin (IVIg)
1/1/2015 | published by: Global Industry Analysts
... and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and ...  |  read more...
USD 4,950
Antibody Drugs: Technologies and Global Markets
1/1/2015 | published by: BCC Research
... between 2014 and 2019 resulting in totals nearly $68.9 billion in 2014 and $122.6 billion globally in 2019. This report provides: An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related ...  |  read more...
USD 6,650
Antibody Partnering Terms and Agreements
1/1/2015 | published by: Current Partnering
... report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right ...  |  read more...
USD 2,995
Emerging Trends in Cell Banking (Technical Insights)
12/29/2014 | published by: Frost & Sullivan
... and comparison with other drugs, or the detection of antidrug antibodies (ADAs) or neutralizing antibodies (NAB), represent critical stages in drug discovery and development. On that note, cells and cell-based reagents constitute the foundations of ...  |  read more...
USD 6,500
Therapeutic Biological Drugs to 2020 Diseases, Devices, Dosing and Forecasts
10/1/2014 | published by: Greystone Research Associates
... sometimes limited by a lack of desirable attributes for adequate absorption or distribution. So it’s critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic and penetration ...  |  read more...
USD 3,850
Single Use Bioreactor Market by Product Type (Recombinant Proteins, Monoclonal Antibodies), Cell Type (Bacteria, Yeast), Technology (Stirred SUB, Single Use Bubble Column Bioreactor), End User(Bio pharmaceutical Manufacturers) - Global Forecast to 2019
11/3/2014 | published by: MarketsandMarkets
... such as China and India are lucrative markets for single-use bioreactors (SUB), owing to the low cost benefits offered by these nations. The report segments the global SUB market by molecule type, type of cell, ...  |  read more...
USD 4,650
Immune Checkpoint Inhibitors Market, 2014-2024
10/11/2014 | published by: Roots Analysis
... forms. Although cancer therapeutics continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, ...  |  read more...
USD 1,899
Anti-CD22 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD22 Antibody. This report provides information on the therapeutic development based on the Anti-CD22 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD25 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD25 Antibody. This report provides information on the therapeutic development based on the Anti-CD25 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD274 (PD-L1) Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... the understanding for all the pipeline drugs that fall under Anti-CD274 (PD-L1) Antibody. This report provides information on the therapeutic development based on the Anti-CD274 (PD-L1) Antibody dealing with mechanism of action, comparative analysis at ...  |  read more...
USD 1,250
Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... the understanding for all the pipeline drugs that fall under Anti-CD279 (PD-1) Antibody. This report provides information on the therapeutic development based on the Anti-CD279 (PD-1) Antibody dealing with mechanism of action, comparative analysis at ...  |  read more...
USD 1,250
Anti-CD3 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD3 Antibody. This report provides information on the therapeutic development based on the Anti-CD3 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD38 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD38 Antibody. This report provides information on the therapeutic development based on the Anti-CD38 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD4 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD4 Antibody. This report provides information on the therapeutic development based on the Anti-CD4 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
< prev 1    3  4  5  6  7  8  9  10